The FDA on January 26, 2023, approved KEYTRUDA® for adjuvant treatment following resection and platinum-based chemotherapy for Stage IB (T2a ≥4 cm), II, or IIIA Non-Small Cell Lung Cancer (NSCLC). KEYTRUDA® is a product of Merck & Co., Inc.
Bottom Ad
Advertisement
Subscribe
